Search En/Fr

THE KEY FINDINGS OF PHASE I

It was feasible to inject NBTXR3 into the tumor mass across different tumor types and volumes (from 55.06 mL to 3682.56 mL)

No leakage of NBTXR3 into the surrounding healthy tissue was observed

NBTXR3 was persistent over time and optimally bioavailable for all sessions of radiotherapy

An appropriate dispersion of NBTXR3 within the tumor in all 3 dimensions was observed

Very good tolerance and local safety of the product was observed at different volumes

Promising signs of antitumor activity were observed in different sarcoma subtypes, such as undifferentiated sarcoma, rhabdomyosarcoma, and synovial sarcoma

The recommended volume for the pivotal study was established

You are here: HEALTHCARE PROFESSIONAL